

~~allow or promote the expression of a gene of interest positioned downstream of said nucleotide sequence.~~

14. (Amended) Retroviral vector according to claim 12 [or 13], in which the encapsidation region is derived from a murine retrovirus, especially from an MoMLV, or from a VL30-type retrotransposon and the IRES site comprises a nucleotide sequence [as defined in claim 6] which is substantially homologous or identical to the sequence presented in the sequence identifier SEQ ID NO: 2:

- (i) starting at nucleotide 1 and ending at nucleotide 578,
- (ii) starting at nucleotide 265 and ending at nucleotide 578, or
- (iii) starting at nucleotide 452 and ending at nucleotide 578.

19. (Amended) Cell comprising a vector according to [one of claims 8 to 17] claim
8 or infected with a viral particle [according to claim 18] generated from a viral vector
according to claim 8.

20. (Amended) Use of a vector according to [one of claims 8 to 17] claim 8, of a viral particle generated from a viral vector according to claim [18] 8 or of a cell comprising a vector according to claim 8 or infected with a virus particle generated from viral vector according to claim [19] 8, for the preparation of a pharmaceutical composition intended for the treatment and/or for the prevention of a disease which is treatable by gene therapy.

21. (Amended) Use of a vector according to [one of claims 8 to 17] claim 8, of a viral particle generated from a viral vector according to claim [18] 8 or of a cell comprising a vector according to claim 8 or infected with a viral vector according to claim [19] 8 for the preparation of one or more polypeptides of interest by the recombinant route or for the protection of a transgenic animal.

22. (Amended) Pharmaceutical composition comprising, as therapeutic or prophylactic agent, a vector according to [one of claims 8 to 17] claim 8, a viral particle generated from a viral vector according to claim [18] 8, a cell comprising a vector according to claim [19] 8 or infected with a viral particle generated from a viral vector according to claim 8, or a polypeptide [of interest obtained according to the use according to claim 21] prepared from said vector, viral particle or cell, in combination with a pharmaceutically acceptable vehicle.

24. (Amended) Use of a vector according to [one of claims 8 to 17] claim 8, of a viral particle [according to claim 18] generated from a viral vector according to claim 8 or of a pharmaceutical composition according to claim 22 or 23 prepared from said vector or viral particle, for the transfection or infection of pluripotent cells, especially pluripotent cells of the central nervous system.

Please amend the remaining claims as follows:

Claim 5, page 38, line 22, please change "one of claims 1 to 4" to --claim 1--.